For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for American Express Company (AXP) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-10-07): Designation Watch · Gem Score +25 (−100…+100 Quality+Value blend) · Quality 67 · Value -3 · Sentiment 11 (timing only, not weighted) · Composite fair value $376.93 vs $329.83 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
American Express Company
AXP NYSEAmerican Express Company is a multinational financial services corporation and bank holding company specializing in premium payment cards and related services. It issues a diverse portfolio of credit, charge, and debit cards under the American Express brand, renowned for their rewards programs, travel perks, and concierge services tailored to high-spending consumers and businesses. The company operates a closed-loop network that directly connects cardmembers, merchants, and partners, facilitating secure transactions worldwide while providing merchants with value-added tools for acceptance and growth. Beyond cards, American Express Company offers business solutions including expense management, commercial financing, and corporate travel services, alongside consumer banking products through American Express National Bank such as high-yield savings accounts and certificates of deposit. Its premium lifestyle brand emphasizes trust, security, and personalized experiences, serving individuals, small businesses, and large corporations across multiple sectors. Founded in 1850 and headquartered in New York, American Express Company plays a pivotal role in the global payments ecosystem, blending technology with exceptional service.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 15.38
Total Equity: $33.47B
Shares: 704,356,307
Total Debt: $57.76B
Cash: $47.79B
EBITDA: N/A
Total Debt: $57.76B
Cash: $47.79B
Revenue: $72.23B
Revenue: $72.23B
Revenue: $72.23B
Total Equity: $33.47B
Tax Rate: 21.5%
Equity: $33.47B
Total Debt: $57.76B
Cash: $47.79B
Current Liabilities: N/A
Long-Term Debt: $56.39B
Total Debt: $57.76B
Total Equity: $33.47B
Shares: 704,356,307
Shares: 704,356,307
CapEx: -$2.43B
Shares: 704,356,307
Stock Price: $336.25
Net Income: $10.83B
Industry Benchmarks
Income Statement (Annual)
Last updated: Jul 30, 2026 5:40pm (69d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $43.1B | $52.6B | $60.4B | $65.9B | $72.2B |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | $11.5B | $12.7B | $13.3B | $14.2B | $15.3B |
| Operating Income | — | — | — | — | — |
| Net Income | $8.1B | $7.5B | $8.4B | $10.1B | $10.8B |
| EBITDA | — | — | — | — | — |
| EPS | $10.04 | $9.86 | $11.23 | $14.04 | $15.41 |
| EPS (Diluted) | $10.02 | $9.85 | $11.21 | $14.01 | $15.38 |
Balance Sheet (Annual)
Last updated: Jul 31, 2026 9:14am (68d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $22.0B | $33.9B | $46.6B | $40.6B | $47.8B |
| Total Current Assets | — | — | — | — | — |
| Total Assets | $188.5B | $228.4B | $261.1B | $271.5B | $300.1B |
| Current Liabilities | — | — | — | — | — |
| Long-Term Debt | $38.7B | $42.6B | $47.9B | $49.7B | $56.4B |
| Total Liabilities | $166.4B | $203.6B | $233.1B | $241.2B | $266.6B |
| Total Equity | $22.2B | $24.7B | $28.1B | $30.3B | $33.5B |
| Retained Earnings | $13.5B | $16.3B | $19.6B | $22.1B | $25.5B |
Cash Flow (Annual)
Last updated: Jul 30, 2026 5:40pm (69d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $14.6B | $21.1B | $18.6B | $14.1B | $18.4B |
| Capital Expenditure | -$1.6B | -$1.9B | -$1.6B | -$1.9B | -$2.4B |
| Free Cash Flow | $13.1B | $19.2B | $17.0B | $12.1B | $16.0B |
| Acquisitions (net) | — | -$15.0M | -$64.0M | -$454.0M | -$633.0M |
| Net Debt Issued / (Repaid) | -$3.9B | $4.3B | $5.0B | $1.8B | $6.2B |
| Dividends Paid | -$1.4B | -$1.6B | -$1.8B | -$2.0B | -$2.3B |
| Stock Buybacks | -$7.7B | -$3.5B | -$3.7B | -$6.0B | -$5.8B |
| Net Change in Cash | -$10.9B | $11.9B | $12.7B | -$6.0B | $7.2B |
Growth Trends (YoY %)
Last updated: Jul 30, 2026 5:40pm (69d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +21.8% | +14.8% | +9.3% | +9.5% |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | — | — | — | — |
| Net Income Growth | -6.8% | +11.4% | +21.0% | +7.0% |
| EBITDA Growth | — | — | — | — |
Dividend History (Last 20)
Last updated: Jul 31, 2026 9:14am (68d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-07-02 | $0.95 | — | — | — |
| 2026-04-02 | $0.95 | — | — | — |
| 2026-01-02 | $0.82 | — | — | — |
| 2025-10-10 | $0.82 | — | — | — |
| 2025-07-03 | $0.82 | — | — | — |
| 2025-04-04 | $0.82 | — | — | — |
| 2025-01-03 | $0.70 | — | — | — |
| 2024-10-04 | $0.70 | — | — | — |
| 2024-07-05 | $0.70 | — | — | — |
| 2024-04-04 | $0.70 | — | — | — |
| 2024-01-04 | $0.60 | — | — | — |
| 2023-10-05 | $0.60 | — | — | — |
| 2023-07-06 | $0.60 | — | — | — |
| 2023-04-05 | $0.60 | — | — | — |
| 2023-01-05 | $0.52 | — | — | — |
| 2022-10-13 | $0.52 | — | — | — |
| 2022-06-30 | $0.52 | — | — | — |
| 2022-04-07 | $0.52 | — | — | — |
| 2022-01-06 | $0.43 | — | — | — |
| 2021-10-07 | $0.43 | — | — | — |
Deep Analysis
Risk : Reward — upside vs downside from this company's own quarters
Computed 2026-10-02 02:03A +1σ run of quarters pays -39%; a −1σ run costs 53%. Ratio -0.7:1 (μ 7.5%, σ 4.3% floored by sector, 16 pairs).
Older method (repeat-worst-quarter): -0.4 : 1
| Case | Growth | Margin | Fair value | vs price ($329.83) |
|---|---|---|---|---|
| Bull — recovery | +13% | 34.5% | $265.20 | -20% |
| Base — stabilizes | +9% | 30.0% | $204.04 | -38% |
| Bear — keeps slipping | +4% | 25.5% | $153.97 | -53% |
| Stress — last quarter repeats | +7% | 26.6% | $174.24 | -47% |
| Upside — a +1σ run of quarters (v2) | +12% | 26.6% | $200.53 | -39% |
| Stress — a −1σ run of quarters (v2) | +3% | 26.6% | $153.64 | -53% |
Narrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-09-03 23:39The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
The raw trajectory here is genuinely strong and I want to start with that before engaging the models. Revenue went from $43.15B (2021) to $72.23B (2025) — a 13.8% CAGR, not the 9.4% the momentum module cites (that looks like a 4-year geometric that undershoots the actual run-rate). Q2 2026 revenue of $11.21B is +8.6% YoY vs Q2 2025's $10.32B, and TTM revenue is roughly $43.1B annualized off the last four quarters implying ~$86B run-rate — that's deceleration from the 2022-2024 pace but still healthy for a $223B mature financial. Net margins have been remarkably stable in the 26-28% band ex-Q4 seasonality (Q4s consistently print ~22% due to reserve builds and rewards accruals — that's a pattern, not deterioration). ROE of 32.4% on 1.68x debt/equity is elite for the sector; Visa runs higher ROE but on a fundamentally different (no credit risk) model. At 21.4x earnings and 3.2x sales, this is not priced for perfection — it's priced roughly in line with the S&P for a business earning double the index ROE.
Where I diverge from the prior models: the Thesis Evaluation's -18 score leans heavily on "insider selling pattern: 14 sellers, zero buyers, $38.8M out" as a 81-weight bear signal. Look at the raw table — the recent activity shown is two sales totaling ~16k shares (roughly $5M at current prices) alongside routine A-Award grants. At a $223B market cap with executive comp heavily equity-denominated, $38.8M of insider selling over presumably many months is noise, not signal. This is programmatic 10b5-1 diversification, not a smoke alarm. The Thesis engine is over-weighting a common false positive. Simultaneously, the Valuation Synthesis's $373 signal-adjusted fair value (+13% upside) and the Thesis's -18 bearish score are directly contradictory — one of them is wrong, and I side with the valuation work. The Narrative layer's "anchored / steady-compounder / minimal intensity" read is the most honest framing in the pack.
The contrarian case worth taking seriously isn't insider selling — it's credit normalization and cyclical exposure. AXP's affluent-skew has been a tailwind through 2022-2025 as high-end consumers outspent the median, but that cohort is not immune to a labor market crack, and Q4 2024 and Q4 2025 already show margin compression to ~22% suggesting provisioning is creeping. FCF CAGR of -3% while earnings CAGR is +13.7% is a real yellow flag — it usually means loan book growth is consuming cash (receivables up), which is fine in expansion and painful in contraction. Debt/equity at 1.68x is manageable but AXP is not a network-only business; it carries real credit risk that Visa and Mastercard don't, and the market's persistent valuation gap (21x vs V/MA at 28-30x) exists for that reason and won't close. The "Lagging Sector Peers" signal likely reflects this — payment networks and pure-play fintechs have re-rated harder.
Net: I partially agree with the Valuation Synthesis's slight-upside read but think +13% upside is optimistic. My own back-of-envelope: 2026E EPS around $16 (extrapolating $3.1B quarterly NI × 4 / ~700M shares ≈ $17.7, haircut for Q4 seasonality to ~$16.50), at a fair 20-22x multiple that supports $330-$363 — right on top of current price. Fair value $340-$355, so the stock is fairly valued to marginally cheap, not the +13% the composite suggests and definitely not the bearish tilt the Thesis Evaluation implies. I dissent from the Thesis's -18 score (methodology flaw on insider weighting) and I'd trim the Synthesis's optimism. This is a compound-at-earnings-growth name, not a re-rating story. Buffett's stake keeps a floor under it; credit cycle keeps a ceiling on the multiple. If you own it, hold. If you don't, you're not missing much at $330 — wait for a credit-scare drawdown to the high-$280s to add with conviction.
GPT Reading
American Express looks like a very good business priced as a very good business, which leaves less valuation slack than some of the softer models imply. The operating picture is undeniably strong: trailing quarterly revenue has stepped from $9.72B in 2024-09 to $11.21B in 2026-06, and the last four quarters sum to roughly $43.1B of revenue with about $11.4B of net income, a ~26.5% quarterly-average margin profile that is exceptional for a lender-exposed card company. Even on annual figures, revenue grew from $60.36B in 2023 to $65.95B in 2024 and $72.23B in 2025, while net income rose from $8.37B to $10.13B to $10.83B. That is not a tired franchise. It is still compounding at a high-single-digit to low-double-digit clip with 32% ROE and $16.0B of free cash flow. The closed-loop model is doing what bulls say it does: producing fee-rich growth, strong member spending, and resilient profitability.
What stands out to me, though, is that the stock price already capitalizes most of that quality. At $329.82 and a $222.7B market cap, investors are paying about 21.4x earnings, 3.2x sales, and nearly 7.0x book for a company whose annual net margin is 15% but whose business remains meaningfully cyclical and credit-sensitive. If I annualize the first half of 2026, you get something like $21.7B revenue over two quarters becoming about $43.5B for six months and, more importantly, about $6.08B of net income in the first half, implying maybe $12.0B-$12.3B for the full year if conditions hold. That would put the stock around 18x-18.5x current-year earnings power, which is not egregious, but also not obviously cheap for a mature financial at a time when growth is decelerating from the stronger post-recovery years. Revenue growth from 2025-06 to 2026-06 was 8.6%; earnings growth was 7.6%. Good, yes. Re-rating fuel, no.
The balance sheet is fine but not the reason to stretch. Debt of $56.39B against $47.79B cash looks manageable in absolute terms, yet this is a financial company where equity of $33.47B supports a large receivables-driven model, so the 6.9x price-to-book matters. You are being asked to underwrite sustained premium economics and benign credit through the cycle. That can work for AXP because its customer base skews affluent, but the valuation gap versus ordinary lenders exists for a reason and should not be hand-waved away. I also don’t put much weight on the “slight upside” fair value output when the hard math says the market already discounts a business that keeps delivering upper-single-digit growth with very high profitability. In other words: the company is outperforming, but the stock knows it.
The strongest pushback to my caution is straightforward: few large-cap financials combine this growth, margin, and cash generation. AXP has increased annual revenue by nearly $29B since 2021, from $43.15B to $72.23B, while sustaining double-digit billions of earnings and generating $18.43B of operating cash flow. Quarterly margins have mostly stayed in the 26%-28% range outside seasonally softer Q4s at 21.8% and 22.5%, which suggests the earnings base is sturdier than skeptics of credit names assume. If full-year 2026 lands around $12B of net income, the current multiple compresses naturally, and a premium multiple versus banks and card lenders is warranted because AXP is partly a network, partly a lender, and wholly a stronger brand than the average credit issuer. That argument is real. I weigh it differently because at 18x-21x earnings and nearly 7x book, you are no longer paying for “better than peers”; you are paying for “better than peers with little stumble risk.”
What would change my mind is either price or proof. On price, I would get constructive below roughly $285, where the earnings multiple would move closer to 15x-16x on a plausible 2026 earnings run-rate and offer a clearer margin of safety for cyclical risk. On proof, I would turn more bullish if AXP can keep revenue above 8% growth while net income grows back into low-teens and quarterly margins stay around 27%-28% through a tougher credit environment, especially if free cash flow rises clearly above the current $16.0B annual mark. Conversely, if revenue slips toward mid-single digits or margins settle closer to the Q4 pattern in the low-20s, the current valuation would look too generous very quickly.
Grok Reading
The numbers describe a high-quality compounder still doing what it has done for years: converting affluent spend and closed-loop fee economics into mid-to-high single-digit top-line growth and faster earnings growth. Annual revenue climbed from $43.15B in 2021 to $72.23B in 2025, a roughly 9.4% CAGR, with 2025 alone up about 9.5% versus 2024’s $65.95B. Earnings CAGR of 13.7% outpaced revenue, lifting net income to $10.83B and producing a 32.4% ROE that pure lenders rarely touch. Recent quarters keep the pattern intact—Q2 2026 revenue $11.21B and NI $3.11B at a 27.7% margin, following Q1’s $10.52B and 28.2%—with the familiar seasonal Q4 margin dip (22.5% in 2025, 21.8% in 2024) rather than structural decay. Free cash flow of $16.0B on $18.43B operating cash flow against only $2.43B capex funds a low 21% payout and a 1.07% yield while still leaving ample capacity for buybacks. At $329.82 and 21.4x earnings, 3.2x sales, and 6.9x book, the market is paying a network-adjacent premium for lender-like credit exposure; that multiple is demanding but not absurd for 9% growth and mid-teens net margins anchored to a sticky affluent base.
What stands out against the more mechanical outputs is how little the underlying series supports the bearish thesis score of –18. The “insider selling pattern” cited as the top bear vector is thin in the actual tape—two modest open-market sales (8,811 and 7,033 shares) amid a cluster of routine awards—and the secondary signal correctly labels insider activity neutral. Market-share-erosion language is asserted harder than the revenue print justifies: recent revenue YoY is still 9.5%, only a mild deceleration from the multi-year CAGR, and quarterly NI margins have re-expanded into the high 20s after the year-end trough. Balance-sheet leverage (debt/equity 1.68, $56.4B debt versus $47.8B cash) is normal for a card issuer and is serviced by that $16B FCF. The valuation synthesis’s composite near $342 and signal-adjusted $373 (+13% from here) lines up better with the cash-flow reality than the aggressive structural-erosion framing. This is a show-me franchise priced on ROE and fee durability, not a narrative stock; the 11–13% discount to those fair-value anchors looks like residual credit-cycle anxiety, not proof the franchise is breaking.
The strongest opposing case starts with the negative FCF CAGR (–3%) and the “decelerating” quarterly revenue tag: if working-capital or loan-growth optics keep suppressing reported FCF while spend growth slips toward mid-single digits, the 21x multiple compresses quickly. AXP sits awkwardly between Visa/Mastercard (30x+) and Capital One (~11x); any sustained share loss in revolving or SME spend, or a recession that normalizes credit losses from today’s pristine levels, re-rates it toward the lender cohort. Macro headwinds and “lagging sector peers” flags are real—travel and corporate T&E are cyclical tailwinds already visible in the 2023–2025 acceleration, so the bar for further upside is higher. Premium ROE can mask rising provision risk until it doesn’t; debt of $56B is manageable only while charge-offs stay benign. I weigh these as cycle and multiple risks, not as evidence the closed-loop moat or 15% net margin is already impaired—the absolute FCF, margin re-expansion in 1H 2026, and earnings growth still above revenue growth keep the burden of proof on the bears.
I would flip to a clear overvalued stance if next two quarters show revenue YoY under 5%, net margins sustaining below 20% outside normal Q4 seasonality, or a material step-up in credit provisions that cuts NI growth to flat. I would become more forcefully bullish on a re-acceleration above 11–12% revenue growth with stable 27%+ quarterly margins and FCF returning to positive high-single-digit CAGR, confirming the affluent moat is still taking share rather than harvesting a late-cycle peak.
Qwen Reading local experiment · off-panel
The number that decides this case is the 32.4% ROE on $33.5B of equity, paired with a clean four-year earnings ramp from $7.51B (2022) to $10.83B (2025) and a TTM net income of $11.44B across the last four quarters. American Express is not a value stock, not a growth stock, and not a value trap — it is a premium credit franchise compounding at 7–10% with a 26–28% net margin in every non-Q4 quarter, and the market is paying roughly 21x for that. That is the middle of its own historical P/E range, not the top.
The quarterly print confirms the trend is intact, not decelerating. Year-over-year, Q2 2026 revenue of $11.21B is up 8.6% from $10.32B a year earlier; Q1 2026's $10.52B is up 9.2% from $9.63B. Net income in the two most recent quarters ($3.11B, $2.97B) is the highest in the eight-quarter window shown. The "decelerating revenue" tag and the "Market Headwinds / value trap" signal from the prior models are not supported by any number in this briefing. The FCF CAGR of −3% is a five-year figure off a base I cannot verify from the data provided, and for a card issuer whose cash flow moves with loan balances and reserve levels, it is not a decision-useful metric in the first place. The "14 sellers, zero buyers, $38.8M out" insider claim in the thesis evaluation is contradicted by the actual transaction log: nine of the last ten entries are A-Awards (compensation grants), and the single S-Sale of 7,033 shares (~$2.4M at $344) is 0.001% of the float — noise, not conviction.
On valuation, the bridge is straightforward for a financial. Market cap $232.4B, cash $47.8B, debt $57.8B, net debt ~$10B. The EV framing is less informative here than the P/E and P/B, because the "debt" is funding for the receivables book and the "cash" is part of the operating model. At $232.4B market cap on $11.44B TTM earnings, the P/E is 20.3x. On 2025 earnings of $10.83B, it is 21.5x. The P/B is 6.9x. Applying the ROE-to-book heuristic: 12% ROE justifies ~1.2x book; each additional 3 points of ROE adds roughly 0.3–0.5x. At 32% ROE, that arithmetic supports 4–5x book, or $134–167B of equity, or $197–247 per share. The market is paying 6.9x, which embeds a premium for the closed-loop network economics, the affluent customer base, and the 9–10% revenue growth that a pure bank at 32% ROE would not command. That premium is reasonable but not generous. A fair P/E for a 32%-ROE financial growing earnings at 7–10% sits at 19–23x, implying $217–263B of equity, or $322–390 per share. At $344, the stock is in the middle of that band.
The strongest case against my "fairly valued" read is the credit-cycle risk that the raw data cannot fully price. AmEx's Q4 margins compress to 22–23% (vs. 27–28% in other quarters) because of seasonal charge-offs and holiday spending patterns; if the macro environment deteriorates and delinquencies in the affluent segment rise, the 26–28% "normal" margin could compress to the low-20s for multiple quarters, and the 32% ROE would fall toward 25%, which would justify a 5x book / 17x P/E re-rating to roughly $280. The 2021→2022 earnings dip ($8.06B → $7.51B) shows the business is not immune to a bad year. The 21% payout ratio leaves ample room for buybacks, but in a downturn the priority shifts to capital preservation, and the 1.03% dividend yield offers no cushion. A smart bear would also note that the 9.4% revenue CAGR is off the 2021 base of $43.15B, and the more recent year-over-year growth (8.6–9.2%) is modest for a company the market is pricing at 21x.
What would change my mind: a Q3 2026 print showing net margin below 25% in a non-Q4 quarter (signaling credit-cost pressure beyond seasonality), a material increase in the delinquency rate on the card portfolio, or a visible deceleration in revenue growth below 5% year-over-year for two consecutive quarters. Conversely, if the company demonstrates sustained 10%+ earnings growth with ROE holding above 33%, the 23x end of my range ($390) becomes the floor, and the "slight upside" call from the valuation synthesis would be conservative.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Revenue has compounded from $43.2B (2021) to $72.2B (2025), roughly 68% cumulative growth, while net income rose from $8.06B to $10.83B and FCF averaged ~$15B/yr. OCF/NI of 1.99x and accruals of -3.5% of assets indicate earnings are backed by cash, not accounting stretch. Diluted share count fell from 804M to 704M (-3.3% CAGR) with buybacks running 1205% of SBC — per-share economics are being concentrated aggressively while SBC is a modest 0.8% of revenue. Capital return discipline is elite for a large-cap financial. The business is a closed-loop payments network with card-issuing, merchant-acquiring, and lending combined — a rare structural moat that produces high-quality fee income (discount revenue) alongside interest income. Liquid cash of $48.5B is large in absolute terms but the company carries net debt of $7.85B, consistent with a lender's balance sheet rather than a fortress. The Altman Z of 0.86 flagged as distress is a false positive: the Z-score is calibrated for industrials/asset-heavy manufacturers, not card issuers whose receivables and funding structure structurally depress the ratio. Insider tape shows routine director awards and modest officer sales (~$41.8M over 12 months, zero open-market buys); mixed, non-directional, unsurprising for a mature earner. The one genuine business-quality caveat is cyclicality: card-issuer earnings are exposed to unemployment and consumer credit; reserve builds in a downturn could compress reported earnings meaningfully even without impairing the franchise.
Verify before trusting this (5)
- Reserve/allowance-for-credit-losses trend and net charge-off rate in the 10-K for cycle positioning
- Card member receivables and loans mix vs total assets to confirm funding structure
- Whether the 15 insider sales in 12 months are 10b5-1 planned dispositions vs discretionary
- Segment split between discount revenue (network) and net interest income (lending) to gauge moat vs credit exposure
- Deposit funding base size and rate sensitivity
Price is $329.83 against a composite DCF fair value of $342.28 (about 4% upside) and a signal-adjusted fair value of $373.18 (about 13% upside). That is a modest, not compelling, margin of safety for a business with genuine credit-cycle exposure. The market is treating AXP as what it is: a high-quality, mature compounder with visible earnings power, and pricing it accordingly. Earnings quality is clean so no haircut to deserved value is warranted, and the Strong quality grade supports paying a full multiple - but paying full price is exactly what buyers are doing here. To justify materially higher prices you need sustained mid-teens EPS growth, benign credit through a cycle, and continued affluent-spend resilience - plausible but not heroic, and largely embedded. There is no dislocation to exploit; the mispricing gap is inside the noise of DCF assumptions.
Verify before trusting this (5)
- Forward card-member loan loss provisions and 30+ day delinquency trend vs guidance
- Billed business growth split between T and E and goods and services - any deceleration in affluent spend
- Net interest yield on card loans as funding costs reset
- Buyback pace and share count trajectory in the next 10-Q
- Management commentary on 2025 EPS algorithm and any softening of the mid-teens growth framework
AXP sits in a quiet sentiment zone. The narrative is a low-intensity, durable steady-compounder story with no cult premium and no active de-rating - the market treats it as a 'show me' cash-flow name, not a story stock. That means neither euphoria nor panic is pressing on the tape; news flow over the last 72 hours is genuinely sleepy (a Ramsey soundbite, a routine peer review, a minor down day) and none of it moves the narrative needle. With beta 1.06, the mildly risk-on regime (+33) offers a small tailwind, but it is only one day old and confidence is medium, so it barely qualifies as a press. Working the other way, 10y at 4.79% and a 25.8 market PE create a real background headwind for a credit-services lender exposed to consumer credit normalization - exactly the bear angle sitting under this name. Momentum is strong-positive (9.4% CAGR, low vol), which quietly supports the tape and keeps the durable-compounder story intact. Net: forces are small and roughly cancel. This is a balanced sentiment read - no dominant press either way, and the stock is likely to trade with the tape rather than on any name-specific narrative pressure.
Verify before trusting this (4)
- Any card-issuer commentary on delinquency or charge-off trends that could awaken the credit-normalization narrative
- 10y yield direction - a break higher would sharpen the rate headwind on financials
- Whether the risk-on regime persists beyond a few sessions or reverses on a VIX spike
- Travel and premium consumer spend data points that either reinforce or crack the compounder story
The world is moving toward more card-based and embedded spend, which lifts the whole category; AXP's defensible slice is the affluent and corporate wallet where brand, rewards and lounge/servicing infrastructure create switching costs fintech entrants cannot cheaply replicate. But the fastest-growing dollars in payments are in mass-market, cross-border and stablecoin/embedded rails where AXP's closed loop is not the winner — hence structural growth at a persistent discount to the category. Rates at 4.79% with a headwind macro tag cut both ways: they support net interest yield while raising funding cost and credit risk. The most likely shape is durable high-single-digit revenue growth with low-double-digit EPS, not an inflection in either direction.
When we made this prediction on Sep 4, 2026, AXP was $327.25. We expect it to be $352.00 by Mar 2027, and we consider it great value under $280.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Sep 4, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.